GlaxoSmithKline Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Bhushan Akshikar
İcra Kurulu Başkanı
₹66.9m
Toplam tazminat
| CEO maaş yüzdesi | 21.7% |
| CEO görev süresi | 1.9yrs |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 2.1yrs |
| Yönetim Kurulu ortalama görev süresi | 6.6yrs |
Son yönetim güncellemeleri
Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹7b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹15m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Tazminat ve Piyasa: Bhushan 'ın toplam tazminatı ($USD 793.32K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 774.00K ).
Tazminat ve Kazançlar: Bhushan 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Bhushan Akshikar
1.9yrs
Görev süresi
₹66,885,000
Tazminat
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Executive Director | 1.9yrs | ₹66.89m | Veri yok | |
| Whole-Time Director & CFO | 2.6yrs | ₹68.92m | Veri yok | |
| Executive Vice President of Human Resources | 3.9yrs | ₹37.40m | Veri yok | |
| Vice President of Technology | less than a year | Veri yok | Veri yok | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | Veri yok | |
| Executive Vice President of Legal | 2.8yrs | Veri yok | Veri yok | |
| Vice President of Ethics & Compliance | 1.8yrs | Veri yok | Veri yok | |
| Executive Vice President of Communications & Government Affairs | 7.6yrs | Veri yok | Veri yok | |
| Executive Vice-President of Regulatory Affairs | no data | Veri yok | Veri yok | |
| Executive Vice-President of Adult Vaccines | 2.3yrs | Veri yok | Veri yok | |
| Executive Vice President of General Medicines | 1.9yrs | Veri yok | Veri yok | |
| Commercial Head - Paediatric Vaccines | 1.8yrs | Veri yok | Veri yok |
2.1yrs
Ortalama Görev Süresi
Deneyimli Yönetim: GLAXO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹66.89m | Veri yok | |
| Whole-Time Director & CFO | 2.6yrs | ₹68.92m | Veri yok | |
| Non-Executive Chairperson | 5.6yrs | ₹3.25m | Veri yok | |
| Independent Director | 2.5yrs | ₹2.65m | Veri yok | |
| Non-Executive Independent Director | 15.3yrs | ₹2.70m | Veri yok | |
| Non Executive Director | 7.6yrs | Veri yok | Veri yok | |
| Non-Executive Independent Director | 14.1yrs | ₹2.70m | Veri yok | |
| Non-Executive Independent Director | 13yrs | ₹2.45m | Veri yok | |
| Non-Executive & Independent Director | 4.5yrs | ₹2.45m | Veri yok |
6.6yrs
Ortalama Görev Süresi
68.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GLAXO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).